Hepatitis b antigen, hepatitisviral antigen
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Glaxosmithkline South Africa (Pty) LimitedCertificate held by Glaxosmithkline South Africa (Pty) Ltd | Twinrix | 1,0 mL | 320244 | Not determined | PIL |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Twinrix EACH 1,0 ml DOSE CONTAINS HEPATITISVIRAL ANTIGEN 720,0 elisa units HEPATITIS B ANTIGEN 20,0 ug | 1,0 mLSuspension for injection. | 32024432/30.1/0244Approved 15 August 2016 | Registered | Not determined | PIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.